Active 0 6 0 6 B-chronic_disease
infection 7 16 7 16 I-chronic_disease
including 17 26 17 26 O
tuberculosis 27 39 27 39 B-chronic_disease
, 39 40 39 40 O
hepatitis 41 50 41 50 B-chronic_disease
B 51 52 51 52 I-chronic_disease
, 52 53 52 53 O
hepatitis 54 63 54 63 B-chronic_disease
C 64 65 64 65 I-chronic_disease
, 65 66 65 66 O
or 67 69 67 69 O
human 70 75 70 75 B-chronic_disease
immunodeficiency 76 92 76 92 I-chronic_disease
virus 93 98 93 98 I-chronic_disease
( 99 100 99 100 I-chronic_disease
HIV 100 103 100 103 I-chronic_disease
) 103 104 103 104 I-chronic_disease

Active 0 6 105 111 O
or 7 9 112 114 O
prior 10 15 115 120 O
documented 16 26 121 131 O
autoimmune 27 37 132 142 B-chronic_disease
or 38 40 143 145 O
inflammatory 41 53 146 158 B-chronic_disease
disorders 54 63 159 168 I-chronic_disease
. 63 64 168 169 O
The 65 68 170 173 O
following 69 78 174 183 O
are 79 82 184 187 O
exceptions 83 93 188 198 O
to 94 96 199 201 O
this 97 101 202 206 O
criterion 102 111 207 216 O
: 111 112 216 217 O
• 113 114 218 219 O
Patients 115 123 220 228 O
with 124 128 229 233 O
vitiligo 129 137 234 242 B-chronic_disease
or 138 140 243 245 O
alopecia 141 149 246 254 B-chronic_disease
• 150 151 255 256 O
Patients 152 160 257 265 O
with 161 165 266 270 O
hypothyroidism 166 180 271 285 B-chronic_disease
( 181 182 286 287 O
eg 182 184 287 289 O
, 184 185 289 290 O
following 186 195 291 300 O
Hashimoto 196 205 301 310 B-chronic_disease
syndrome 206 214 311 319 I-chronic_disease
) 214 215 319 320 O
stable 216 222 321 327 O
on 223 225 328 330 O
hormone 226 233 331 338 B-treatment
replacement 234 245 339 350 I-treatment
• 246 247 351 352 O
Any 248 251 353 356 O
chronic 252 259 357 364 O
skin 260 264 365 369 O
condition 265 274 370 379 O
that 275 279 380 384 O
does 280 284 385 389 O
not 285 288 390 393 O
require 289 296 394 401 O
systemic 297 305 402 410 B-treatment
therapy 306 313 411 418 I-treatment
• 314 315 419 420 O
Patients 316 324 421 429 O
without 325 332 430 437 O
active 333 339 438 444 O
disease 340 347 445 452 O
in 348 350 453 455 O
the 351 354 456 459 O
last 355 359 460 464 B-upper_bound
3 360 361 465 466 I-upper_bound
years 362 367 467 472 I-upper_bound
may 368 371 473 476 O
be 372 374 477 479 O
included 375 383 480 488 O
but 384 387 489 492 O
only 388 392 493 497 O
after 393 398 498 503 O
consultation 399 411 504 516 O
with 412 416 517 521 O
AstraZeneca 417 428 522 533 O
• 429 430 534 535 O
Patients 431 439 536 544 O
with 440 444 545 549 O
celiac 445 451 550 556 B-chronic_disease
disease 452 459 557 564 I-chronic_disease
controlled 460 470 565 575 O
by 471 473 576 578 O
diet 474 478 579 583 O
alone 479 484 584 589 O
may 485 488 590 593 O
be 489 491 594 596 O
included 492 500 597 605 O
but 501 504 606 609 O
only 505 509 610 614 O
after 510 515 615 620 O
consultation 516 528 621 633 O
with 529 533 634 638 O
AstraZeneca 534 545 639 650 O

Brain 0 5 651 656 B-cancer
metastases 6 16 657 667 I-cancer
or 17 19 668 670 O
spinal 20 26 671 677 B-chronic_disease
cord 27 31 678 682 I-chronic_disease
compression 32 43 683 694 I-chronic_disease
unless 44 50 695 701 O
the 51 54 702 705 O
patient 55 62 706 713 O
's 62 64 713 715 O
condition 65 74 716 725 O
is 75 77 726 728 O
stable 78 84 729 735 O
and 85 88 736 739 O
off 89 92 740 743 O
steroids 93 101 744 752 B-treatment
for 102 105 753 756 O
at 106 108 757 759 O
least 109 114 760 765 O
14 115 117 766 768 B-lower_bound
days 118 122 769 773 I-lower_bound
prior 123 128 774 779 I-lower_bound
to 129 131 780 782 O
the 132 135 783 786 O
start 136 141 787 792 O
of 142 144 793 795 O
study 145 150 796 801 B-treatment
treatment 151 160 802 811 I-treatment
. 160 161 811 812 O
Patients 162 170 813 821 O
with 171 175 822 826 O
suspected 176 185 827 836 O
or 186 188 837 839 O
known 189 194 840 845 O
brain 195 200 846 851 B-cancer
metastases 201 211 852 862 I-cancer
at 212 214 863 865 O
screening 215 224 866 875 O
should 225 231 876 882 O
have 232 236 883 887 O
an 237 239 888 890 O
MRI 240 243 891 894 B-treatment
( 244 245 895 896 O
preferred)/CT 245 258 896 909 O
, 258 259 909 910 O
preferably 260 270 911 921 O
with 271 275 922 926 O
IV 276 278 927 929 O
contrast 279 287 930 938 O
to 288 290 939 941 O
access 291 297 942 948 O
baseline 298 306 949 957 O
disease 307 314 958 965 O
status 315 321 966 972 O

Creatinine 0 10 973 983 B-clinical_variable
clearance 11 20 984 993 I-clinical_variable
( 21 22 994 995 O
calculated 22 32 995 1005 O
or 33 35 1006 1008 O
measured 36 44 1009 1017 O
) 44 45 1017 1018 O
< 46 47 1019 1020 O
60 47 49 1020 1022 B-upper_bound
mL 50 52 1023 1025 I-upper_bound
/ 52 53 1025 1026 I-upper_bound
min 53 56 1026 1029 I-upper_bound
calculated 57 67 1030 1040 O
by 68 70 1041 1043 O
Cockcroft 71 80 1044 1053 O
- 80 81 1053 1054 O
Gault 81 86 1054 1059 O
equation 87 95 1060 1068 O
( 96 97 1069 1070 O
using 97 102 1070 1075 O
actual 103 109 1076 1082 O
body 110 114 1083 1087 O
weight 115 121 1088 1094 O
) 121 122 1094 1095 O
or 123 125 1096 1098 O
by 126 128 1099 1101 O
measured 129 137 1102 1110 O
24 138 140 1111 1113 B-lower_bound
- 140 141 1113 1114 O
hour 141 145 1114 1118 O
urine 146 151 1119 1124 O
collection 152 162 1125 1135 O
for 163 166 1136 1139 O
determination 167 180 1140 1153 O
• 181 182 1154 1155 O
Common 183 189 1156 1162 B-clinical_variable
Terminology 190 201 1163 1174 I-clinical_variable
Criteria 202 210 1175 1183 I-clinical_variable
for 211 214 1184 1187 I-clinical_variable
Adverse 215 222 1188 1195 I-clinical_variable
Events 223 229 1196 1202 I-clinical_variable
( 230 231 1203 1204 I-clinical_variable
CTCAE 231 236 1204 1209 I-clinical_variable
) 236 237 1209 1210 I-clinical_variable
Grade 238 243 1211 1216 I-clinical_variable
≥2 244 246 1217 1219 O
audiometric 247 258 1220 1231 O
hearing 259 266 1232 1239 B-chronic_disease
loss 267 271 1240 1244 I-chronic_disease
• 272 273 1245 1246 O
CTCAE 274 279 1247 1252 B-clinical_variable
Grade 280 285 1253 1258 I-clinical_variable
≥2 286 288 1259 1261 O
peripheral 289 299 1262 1272 B-chronic_disease
neuropathy 300 310 1273 1283 I-chronic_disease
• 311 312 1284 1285 O
New 313 316 1286 1289 O
York 317 321 1290 1294 O
Heart 322 327 1295 1300 O
Association 328 339 1301 1312 O
≥Class 340 346 1313 1319 O
III 347 350 1320 1323 I-lower_bound
heart 351 356 1324 1329 B-chronic_disease
failure 357 364 1330 1337 I-chronic_disease

Current 0 7 1338 1345 O
or 8 10 1346 1348 O
prior 11 16 1349 1354 O
use 17 20 1355 1358 O
of 21 23 1359 1361 O
immunosuppressive 24 41 1362 1379 B-treatment
medication 42 52 1380 1390 I-treatment
within 53 59 1391 1397 O
14 60 62 1398 1400 B-upper_bound
days 63 67 1401 1405 I-upper_bound
before 68 74 1406 1412 O
the 75 78 1413 1416 O
first 79 84 1417 1422 O
dose 85 89 1423 1427 O
of 90 92 1428 1430 O
investigational 93 108 1431 1446 B-treatment
product 109 116 1447 1454 I-treatment
( 117 118 1455 1456 I-treatment
IP 118 120 1456 1458 I-treatment
) 120 121 1458 1459 I-treatment
. 121 122 1459 1460 O
The 123 126 1461 1464 O
following 127 136 1465 1474 O
are 137 140 1475 1478 O
exceptions 141 151 1479 1489 O
to 152 154 1490 1492 O
this 155 159 1493 1497 O
criterion 160 169 1498 1507 O
: 169 170 1507 1508 O
• 171 172 1509 1510 O
Intranasal 173 183 1511 1521 B-treatment
, 183 184 1521 1522 O
inhaled 185 192 1523 1530 B-treatment
, 192 193 1530 1531 O
topical 194 201 1532 1539 B-treatment
steroids 202 210 1540 1548 I-treatment
, 210 211 1548 1549 O
or 212 214 1550 1552 O
local 215 220 1553 1558 B-treatment
steroid 221 228 1559 1566 I-treatment
injections 229 239 1567 1577 I-treatment
( 240 241 1578 1579 O
eg 241 243 1579 1581 O
, 243 244 1581 1582 O
intra 245 250 1583 1588 B-treatment
articular 251 260 1589 1598 I-treatment
injection 261 270 1599 1608 I-treatment
) 270 271 1608 1609 O
• 272 273 1610 1611 O
Systemic 274 282 1612 1620 B-treatment
corticosteroids 283 298 1621 1636 I-treatment
at 299 301 1637 1639 O
physiologic 302 313 1640 1651 B-treatment
doses 314 319 1652 1657 I-treatment
not 320 323 1658 1661 O
to 324 326 1662 1664 O
exceed 327 333 1665 1671 O
10 334 336 1672 1674 B-upper_bound
mg 337 339 1675 1677 I-upper_bound
/ 339 340 1677 1678 O
day 340 343 1678 1681 O
of 344 346 1682 1684 O
prednisone 347 357 1685 1695 B-treatment
or 358 360 1696 1698 O
its 361 364 1699 1702 O
equivalent 365 375 1703 1713 O
• 376 377 1714 1715 O
Steroids 378 386 1716 1724 B-treatment
as 387 389 1725 1727 O
premedication 390 403 1728 1741 O
for 404 407 1742 1745 O
hypersensitivity 408 424 1746 1762 O
reactions 425 434 1763 1772 O
( 435 436 1773 1774 O
eg 436 438 1774 1776 O
, 438 439 1776 1777 O
CT 440 442 1778 1780 B-treatment
scan 443 447 1781 1785 I-treatment
premedication 448 461 1786 1799 I-treatment
) 461 462 1799 1800 O

History 0 7 1801 1808 O
of 8 10 1809 1811 O
allogenic 11 20 1812 1821 B-treatment
organ 21 26 1822 1827 I-treatment
transplantation 27 42 1828 1843 I-treatment
that 43 47 1844 1848 O
requires 48 56 1849 1857 O
use 57 60 1858 1861 O
of 61 63 1862 1864 O
immunosuppressive 64 81 1865 1882 B-treatment
agents 82 88 1883 1889 I-treatment

Patients 0 8 1890 1898 O
eligible 9 17 1899 1907 O
or 18 20 1908 1910 O
ineligible 21 31 1911 1921 O
for 32 35 1922 1925 O
cisplatin 36 45 1926 1935 B-treatment
- 45 46 1935 1936 I-treatment
based 46 51 1936 1941 I-treatment
chemotherapy 52 64 1942 1954 I-treatment

Patients 0 8 1955 1963 O
with 9 13 1964 1968 O
histologically 14 28 1969 1983 O
or 29 31 1984 1986 O
cytologically 32 45 1987 2000 O
documented 46 56 2001 2011 O
, 56 57 2011 2012 O
unresectable 58 70 2013 2025 O
, 70 71 2025 2026 O
Stage 72 77 2027 2032 B-cancer
IV 78 80 2033 2035 I-cancer
transitional 81 93 2036 2048 I-cancer
cell 94 98 2049 2053 I-cancer
carcinoma 99 108 2054 2063 I-cancer
of 109 111 2064 2066 I-cancer
the 112 115 2067 2070 I-cancer
urothelium 116 126 2071 2081 I-cancer
who 127 130 2082 2085 O
have 131 135 2086 2090 O
not 136 139 2091 2094 O
been 140 144 2095 2099 O
previously 145 155 2100 2110 O
treated 156 163 2111 2118 O
with 164 168 2119 2123 O
first 169 174 2124 2129 B-treatment
- 174 175 2129 2130 I-treatment
line 175 179 2130 2134 I-treatment
chemotherapy 180 192 2135 2147 I-treatment

Prior 0 5 2148 2153 O
exposure 6 14 2154 2162 O
to 15 17 2163 2165 O
immune 18 24 2166 2172 B-treatment
- 24 25 2172 2173 I-treatment
mediated 25 33 2173 2181 I-treatment
therapy 34 41 2182 2189 I-treatment
, 41 42 2189 2190 O
including 43 52 2191 2200 O
but 53 56 2201 2204 O
not 57 60 2205 2208 O
limited 61 68 2209 2216 O
to 69 71 2217 2219 O
, 71 72 2219 2220 O
other 73 78 2221 2226 O
anti 79 83 2227 2231 B-treatment
cytotoxic 84 93 2232 2241 I-treatment
T 94 95 2242 2243 I-treatment
- 95 96 2243 2244 I-treatment
lymphocyte 96 106 2244 2254 I-treatment
- 106 107 2254 2255 I-treatment
associated 107 117 2255 2265 I-treatment
protein 118 125 2266 2273 I-treatment
4 126 127 2274 2275 I-treatment
( 128 129 2276 2277 I-treatment
CTLA 129 133 2277 2281 I-treatment
4 134 135 2282 2283 I-treatment
) 135 136 2283 2284 I-treatment
, 136 137 2284 2285 O
anti 138 142 2286 2290 B-treatment
- 142 143 2290 2291 I-treatment
PD-1 143 147 2291 2295 I-treatment
, 147 148 2295 2296 O
anti 149 153 2297 2301 B-treatment
- 153 154 2301 2302 I-treatment
PD 154 156 2302 2304 I-treatment
- 156 157 2304 2305 I-treatment
L1 157 159 2305 2307 I-treatment
, 159 160 2307 2308 O
or 161 163 2309 2311 O
anti 164 168 2312 2316 B-treatment
- 168 169 2316 2317 I-treatment
PD 169 171 2317 2319 I-treatment
- 171 172 2319 2320 I-treatment
L2 172 174 2320 2322 I-treatment
antibodies 175 185 2323 2333 I-treatment
, 185 186 2333 2334 O
including 187 196 2335 2344 O
therapeutic 197 208 2345 2356 B-treatment
anticancer 209 219 2357 2367 I-treatment
vaccines 220 228 2368 2376 I-treatment
. 228 229 2376 2377 O
Prior 230 235 2378 2383 O
local 236 241 2384 2389 O
intervesical 242 254 2390 2402 B-treatment
chemotherapy 255 267 2403 2415 I-treatment
or 268 270 2416 2418 O
immunotherapy 271 284 2419 2432 B-treatment
is 285 287 2433 2435 O
allowed 288 295 2436 2443 O
if 296 298 2444 2446 O
completed 299 308 2447 2456 O
at 309 311 2457 2459 O
least 312 317 2460 2465 O
28 318 320 2466 2468 B-lower_bound
days 321 325 2469 2473 I-lower_bound
prior 326 331 2474 2479 I-lower_bound
to 332 334 2480 2482 O
the 335 338 2483 2486 O
initiation 339 349 2487 2497 O
of 350 352 2498 2500 O
study 353 358 2501 2506 O
treatment 359 368 2507 2516 O

Receipt 0 7 2517 2524 O
of 8 10 2525 2527 O
live 11 15 2528 2532 B-treatment
attenuated 16 26 2533 2543 I-treatment
vaccine 27 34 2544 2551 I-treatment
within 35 41 2552 2558 O
30 42 44 2559 2561 B-upper_bound
days 45 49 2562 2566 I-upper_bound
prior 50 55 2567 2572 I-upper_bound
to 56 58 2573 2575 O
the 59 62 2576 2579 O
first 63 68 2580 2585 O
dose 69 73 2586 2590 O
of 74 76 2591 2593 O
IP 77 79 2594 2596 B-treatment
. 79 80 2596 2597 O
Note 81 85 2598 2602 O
: 85 86 2602 2603 O
Patients 87 95 2604 2612 O
, 95 96 2612 2613 O
if 97 99 2614 2616 O
enrolled 100 108 2617 2625 O
, 108 109 2625 2626 O
should 110 116 2627 2633 O
not 117 120 2634 2637 O
receive 121 128 2638 2645 O
live 129 133 2646 2650 O
vaccine 134 141 2651 2658 O
during 142 148 2659 2665 O
the 149 152 2666 2669 O
study 153 158 2670 2675 O
and 159 162 2676 2679 O
up 163 165 2680 2682 O
to 166 168 2683 2685 O
30 169 171 2686 2688 O
days 172 176 2689 2693 O
after 177 182 2694 2699 O
the 183 186 2700 2703 O
last 187 191 2704 2708 O
dose 192 196 2709 2713 O
of 197 199 2714 2716 O
IP 200 202 2717 2719 O

Tumor 0 5 2720 2725 B-cancer
PD 6 8 2726 2728 I-cancer
- 8 9 2728 2729 I-cancer
L1 9 11 2729 2731 I-cancer
status 12 18 2732 2738 O
, 18 19 2738 2739 O
with 20 24 2740 2744 O
Immunohistochemical 25 44 2745 2764 B-treatment
( 45 46 2765 2766 I-treatment
IHC 46 49 2766 2769 I-treatment
) 49 50 2769 2770 I-treatment
assay 51 56 2771 2776 I-treatment
confirmed 57 66 2777 2786 O
by 67 69 2787 2789 O
a 70 71 2790 2791 O
reference 72 81 2792 2801 O
laboratory 82 92 2802 2812 O
, 92 93 2812 2813 O
must 94 98 2814 2818 O
be 99 101 2819 2821 O
known 102 107 2822 2827 O
prior 108 113 2828 2833 O
to 114 116 2834 2836 O
randomization 117 130 2837 2850 O

